Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Plasmablastic Lymphoma × Bortezomib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 187 Lymphoma, Mantle-Cell 34 Neoplasms, Plasma Cell 32 Lymphoma 32 Recurrence 26 Lymphoma, Follicular 20 Waldenstrom Macroglobulinemia 18 Lymphoma, Non-Hodgkin 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Lymphoma, Large B-Cell, Diffuse 13 Lymphoma, B-Cell, Marginal Zone 13 Carcinoma, Non-Small-Cell Lung 13 Immunoglobulin Light-chain Amyloidosis 10 Neoplasms 9 Leukemia, Myeloid, Acute 9 Lymphoma, B-Cell 8 Renal Insufficiency 7 Leukemia, Lymphocytic, Chronic, B-Cell 7 Leukemia 7 Hodgkin Disease 6 Lymphoma, T-Cell, Peripheral 5 Lymphoma, T-Cell 5 Prostatic Neoplasms 4 Myelodysplastic Syndromes 4 Kidney Neoplasms 4 Carcinoma, Renal Cell 4 Breast Neoplasms 4 Brain Neoplasms 4 Amyloidosis 4 Stomach Neoplasms 3

Interventions

varlilumab 1 daratumumab 1 belantamab mafodotin 1 Vincristine 1 Rituximab 1 Prednisone 1 Nivolumab 1 Immunoglobulin G 1 Etoposide 1 Doxorubicin 1 Disulfides 1 Dexamethasone 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡